

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

| APPLICATION NO.                           | FILING DATE     | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO.      | CONFIRMATION NO |
|---|-----------------|----------------------|--------------------------|-----------------|
| 10/621,485                                | 07/16/2003      | Mike Mueckler        | 56029/41936              | 3332            |
| 21888                                     | 7590 12/22/2004 |                      | EXAMINER                 |                 |
| THOMPSON COBURN, LLP<br>ONE US BANK PLAZA |                 |                      | · FERNANDEZ, SUSAN EMILY |                 |
| SUITE 3500                                | IKTLAZA         |                      | ART UNIT                 | PAPER NUMBER    |
| ST LOUIS, MO 63101                        |                 |                      | 1651                     |                 |

DATE MAILED: 12/22/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

| ·   | Application No.   | Applicant(s)    |  |  |  |
|---|---|-----------------|--|--|--|
|   | 10/621,485  | MUECKLER ET AL. |  |  |  |
| Office Action Summary   | Examiner  | Art Unit        |  |  |  |
|   | Susan E. Fernandez  | 1651            |  |  |  |
| The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply  |   |                 |  |  |  |
| A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). |   |                 |  |  |  |
| Status  |   |                 |  |  |  |
| 1) Responsive to communication(s) filed on  |   | !               |  |  |  |
| 2a) This action is <b>FINAL</b> . 2b) ⊠ Thi   | s action is <b>FINAL</b> . 2b) This action is non-final.                    |                 |  |  |  |
| 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.  |   |                 |  |  |  |
| Disposition of Claims   |   |                 |  |  |  |
| 4) Claim(s) 1-29 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration.  5) Claim(s) is/are allowed.  6) Claim(s) is/are rejected.  7) Claim(s) is/are objected to.  8) Claim(s) 1-29 are subject to restriction and/or election requirement.  |   |                 |  |  |  |
| Application Papers  |   |                 |  |  |  |
| 9)☐ The specification is objected to by the Examiner.   |   |                 |  |  |  |
| 10) The drawing(s) filed on is/are: a) □ accepted or b) □ objected to by the Examiner.  |   |                 |  |  |  |
| Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).   |   |                 |  |  |  |
| Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.  |   |                 |  |  |  |
| Priority under 35 U.S.C. § 119  |   |                 |  |  |  |
| <ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No.</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>  |   |                 |  |  |  |
| Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)  Paper No(s)/Mail Date  | 4) Interview Summary Paper No(s)/Mail D  5) Notice of Informal F  6) Other: |                 |  |  |  |

Application/Control Number: 10/621,485

Art Unit: 1651

## **DETAILED ACTION**

Claims 1-29 are presented for examination.

## Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-15 and 22, drawn to an in vitro method of activating protein kinase B, classified in class 435, subclass 194.
- II. Claims 16-17, drawn to an in vitro method of phosphorylating a serine of protein kinase B, classified in class 435, subclass 194.
- III. Claims 18-21 and 23-26, drawn to an in vitro method of identifying an agent that modulates insulin activity, classified in class 435, subclass 15.
- IV. Claims 27-29, drawn to a composition comprising a prepared membrane fraction comprising an enzyme having PDK2 activity obtained from a cell, classified in class 435, subclass 194.

The inventions are distinct, each from the other because of the following reasons:

Although there are no provisions under the section for "Relationship of Inventions" in M.P.E.P. § 806.05 for inventive groups that are directed to different methods, restriction is deemed to be proper because these methods appear to constitute patentably distinct inventions for the following reasons: Groups I, II, and III are directed to methods that are distinct both physically and functionally, and are not required one for the other. Group I requires that the threonine residue of protein kinase B is phosphorylated and that protein kinase B is capable of

Application/Control Number: 10/621,485

Art Unit: 1651

phosphorylating a GSK3, which is not required by groups II and III. Furthermore, Group III provides the specific requirements of the inclusion of particular types of protein kinase activities and an insulin receptor. These are not required by any of the other groups. Therefore, a search and examination of all three methods in one patent application would result in an undue burden, since the searches for the methods are not co-extensive, the classification is different, and the subject matter is divergent.

The products of Invention IV are separate and distinct from the methods of Inventions I-III, wherein the compositions of Invention IV may neither be made by nor used in the methods of Inventions I-III, and wherein each does not require the other. Specifically, the compositions of Invention IV only comprise a prepared membrane fraction and do not require a cytoplasmic fraction which is needed for the methods of Inventions I-III. Accordingly, restriction is proper.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the

Application/Control Number: 10/621,485

Art Unit: 1651

currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Susan E. Fernandez whose telephone number is (571) 272-3444. The examiner can normally be reached on Mon-Fri 8:30 am - 5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mike Wityshyn can be reached on (571) 272-0926. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Susan E. Fernandez Assistant Examiner Art Unit 1651

sef

FRANCISCO PRATS